Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Remon J, Mezquita L, Corral J, Vilariño N, Reguart N.

J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52. Review.

2.

Optimizing feed frame design and tableting process parameters to increase die-filling uniformity on a high-speed rotary tablet press.

Grymonpré W, Vanhoorne V, Van Snick B, Blahova Prudilova B, Detobel F, Remon JP, De Beer T, Vervaet C.

Int J Pharm. 2018 Jun 22;548(1):54-61. doi: 10.1016/j.ijpharm.2018.06.047. [Epub ahead of print]

PMID:
29940299
3.

Influence of extended dwell time during pre- and main compression on the properties of ibuprofen tablets.

Peeters E, Silva AFT, Fonteyne M, De Beer T, Vervaet C, Remon JP.

Eur J Pharm Biopharm. 2018 Jul;128:300-315. doi: 10.1016/j.ejpb.2018.05.007. Epub 2018 May 4.

PMID:
29733949
4.

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

Remon J, Besse B.

Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018. Review.

5.

A novel approach to support formulation design on twin screw wet granulation technology: Understanding the impact of overarching excipient properties on drug product quality attributes.

Willecke N, Szepes A, Wunderlich M, Remon JP, Vervaet C, De Beer T.

Int J Pharm. 2018 Jul 10;545(1-2):128-143. doi: 10.1016/j.ijpharm.2018.04.017. Epub 2018 Apr 21.

PMID:
29684559
6.

Process monitoring and evaluation of a continuous pharmaceutical twin-screw granulation and drying process using multivariate data analysis.

Silva AF, Vercruysse J, Vervaet C, Remon JP, Lopes JA, De Beer T, Sarraguça MC.

Eur J Pharm Biopharm. 2018 Jul;128:36-47. doi: 10.1016/j.ejpb.2018.04.011. Epub 2018 Apr 16.

PMID:
29673869
7.

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.

Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A.

J Natl Cancer Inst. 2018 Feb 26. doi: 10.1093/jnci/djy012. [Epub ahead of print]

PMID:
29529211
8.

Are liquid biopsies a surrogate for tissue EGFR testing?

Goldman JW, Noor ZS, Remon J, Besse B, Rosenfeld N.

Ann Oncol. 2018 Jan 1;29(suppl_1):i38-i46. doi: 10.1093/annonc/mdx706.

PMID:
29462257
9.

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.

Remon J, Steuer CE, Ramalingam SS, Felip E.

Ann Oncol. 2018 Jan 1;29(suppl_1):i20-i27. doi: 10.1093/annonc/mdx704.

PMID:
29462255
10.

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.

Remon J, Vilariño N, Reguart N.

Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29454155
11.

Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2018 Mar;117:80. doi: 10.1016/j.lungcan.2017.11.007. Epub 2018 Feb 3. No abstract available.

PMID:
29398170
12.

Processing of Citrus Nanostructured Cellulose: A Rigorous Design-of-Experiment Study of the Hydrothermal Microwave-Assisted Selective Scissoring Process.

Matharu AS, de Melo EM, Remón J, Wang S, Abdulina A, Kontturi E.

ChemSusChem. 2018 Apr 25;11(8):1344-1353. doi: 10.1002/cssc.201702456. Epub 2018 Mar 25.

PMID:
29377596
13.

Breakage and drying behaviour of granules in a continuous fluid bed dryer: Influence of process parameters and wet granule transfer.

De Leersnyder F, Vanhoorne V, Bekaert H, Vercruysse J, Ghijs M, Bostijn N, Verstraeten M, Cappuyns P, Van Assche I, Vander Heyden Y, Ziemons E, Remon JP, Nopens I, Vervaet C, De Beer T.

Eur J Pharm Sci. 2018 Mar 30;115:223-232. doi: 10.1016/j.ejps.2018.01.037.

PMID:
29374528
14.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

PMID:
29327044
15.

Downstream processing from melt granulation towards tablets: In-depth analysis of a continuous twin-screw melt granulation process using polymeric binders.

Grymonpré W, Verstraete G, Vanhoorne V, Remon JP, De Beer T, Vervaet C.

Eur J Pharm Biopharm. 2018 Mar;124:43-54. doi: 10.1016/j.ejpb.2017.12.005. Epub 2017 Dec 14.

PMID:
29248561
16.

3D printing of high drug loaded dosage forms using thermoplastic polyurethanes.

Verstraete G, Samaro A, Grymonpré W, Vanhoorne V, Van Snick B, Boone MN, Hellemans T, Van Hoorebeke L, Remon JP, Vervaet C.

Int J Pharm. 2018 Jan 30;536(1):318-325. doi: 10.1016/j.ijpharm.2017.12.002. Epub 2017 Dec 5.

PMID:
29217471
17.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B.

Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7.

PMID:
29191602
18.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
19.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

PMID:
28961841
20.

Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy.

Mazza C, Remon J, Honoré C, Besse B.

Lung Cancer. 2017 Sep;111:59-60. doi: 10.1016/j.lungcan.2017.06.011. Epub 2017 Jul 8.

PMID:
28838398
21.

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

Jovelet C, Madic J, Remon J, Honoré A, Girard R, Rouleau E, André B, Besse B, Droniou M, Lacroix L.

PLoS One. 2017 Aug 22;12(8):e0183319. doi: 10.1371/journal.pone.0183319. eCollection 2017.

22.

Downstream processing from hot-melt extrusion towards tablets: A quality by design approach.

Grymonpré W, Bostijn N, Herck SV, Verstraete G, Vanhoorne V, Nuhn L, Rombouts P, Beer T, Remon JP, Vervaet C.

Int J Pharm. 2017 Oct 5;531(1):235-245. doi: 10.1016/j.ijpharm.2017.08.077. Epub 2017 Aug 18.

PMID:
28823887
23.

Development of a continuous direct compression platform for low-dose drug products.

Van Snick B, Holman J, Vanhoorne V, Kumar A, De Beer T, Remon JP, Vervaet C.

Int J Pharm. 2017 Aug 30;529(1-2):329-346. doi: 10.1016/j.ijpharm.2017.07.003. Epub 2017 Jul 4.

PMID:
28684361
24.

Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis.

Verstraete G, Vandenbussche L, Kasmi S, Nuhn L, Brouckaert D, Van Renterghem J, Grymonpré W, Vanhoorne V, Coenye T, De Geest BG, De Beer T, Remon JP, Vervaet C.

Int J Pharm. 2017 Aug 30;529(1-2):218-226. doi: 10.1016/j.ijpharm.2017.06.076. Epub 2017 Jun 27.

PMID:
28663088
25.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E.

Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

PMID:
28660482
26.

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.

PMID:
28633480
27.

Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.

Gion M, Remon J, Caramella C, Soria JC, Besse B.

Lung Cancer. 2017 Jun;108:72-74. doi: 10.1016/j.lungcan.2017.02.022. Epub 2017 Feb 27.

PMID:
28625652
28.

CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

Remon J, Abedallaa N, Taranchon-Clermont E, Bluthgen V, Lindsay CR, Besse B, Thomas de Montpréville V.

Lung Cancer. 2017 Jun;108:168-172. doi: 10.1016/j.lungcan.2017.03.019. Epub 2017 Mar 31.

PMID:
28625631
29.

Multivariate statistical process control of a continuous pharmaceutical twin-screw granulation and fluid bed drying process.

Silva AF, Sarraguça MC, Fonteyne M, Vercruysse J, De Leersnyder F, Vanhoorne V, Bostijn N, Verstraeten M, Vervaet C, Remon JP, De Beer T, Lopes JA.

Int J Pharm. 2017 Aug 7;528(1-2):242-252. doi: 10.1016/j.ijpharm.2017.05.075. Epub 2017 Jun 2.

PMID:
28583334
30.

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.

Planchard D, Remon J, Nowak F, Soria JC.

Am Soc Clin Oncol Educ Book. 2017;37:12-17. doi: 10.14694/EDBK_100007. No abstract available.

31.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.

32.

A step towards the harmonization of clinical trials inform consent forms.

Remon J, Ferté C.

Ann Oncol. 2017 May 1;28(5):910-912. doi: 10.1093/annonc/mdx082. No abstract available.

PMID:
28453709
33.

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Remon J, Besse B, Soria JC.

BMC Med. 2017 Apr 20;15(1):82. doi: 10.1186/s12916-017-0857-x. No abstract available.

34.

Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.

Remon J, Soria JC.

Ann Oncol. 2017 Feb 1;28(2):196-198. doi: 10.1093/annonc/mdw553. No abstract available.

PMID:
28426099
35.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.

Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.

36.
37.

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6. Review. Erratum in: Lung Cancer. 2018 Feb 1;:.

PMID:
28285697
38.

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Remon J, Besse B, Soria JC.

BMC Med. 2017 Mar 13;15(1):55. doi: 10.1186/s12916-017-0819-3. Review. Erratum in: BMC Med. 2017 Apr 20;15(1):82.

39.

Identifying overarching excipient properties towards an in-depth understanding of process and product performance for continuous twin-screw wet granulation.

Willecke N, Szepes A, Wunderlich M, Remon JP, Vervaet C, De Beer T.

Int J Pharm. 2017 Apr 30;522(1-2):234-247. doi: 10.1016/j.ijpharm.2017.02.028. Epub 2017 Feb 14.

PMID:
28213278
40.

Cranberry extract inhibits in vitro adhesion of F4 and F18+Escherichia coli to pig intestinal epithelium and reduces in vivo excretion of pigs orally challenged with F18+ verotoxigenic E. coli.

Coddens A, Loos M, Vanrompay D, Remon JP, Cox E.

Vet Microbiol. 2017 Apr;202:64-71. doi: 10.1016/j.vetmic.2017.01.019. Epub 2017 Jan 20.

PMID:
28161211
41.

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

Remon J, Le Rhun E, Besse B.

Cancer Treat Rev. 2017 Feb;53:128-137. doi: 10.1016/j.ctrv.2016.12.006. Epub 2016 Dec 30. Review.

PMID:
28110254
42.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.

PMID:
28104619
43.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

44.

Continuous direct compression as manufacturing platform for sustained release tablets.

Van Snick B, Holman J, Cunningham C, Kumar A, Vercruysse J, De Beer T, Remon JP, Vervaet C.

Int J Pharm. 2017 Mar 15;519(1-2):390-407. doi: 10.1016/j.ijpharm.2017.01.010. Epub 2017 Jan 6.

PMID:
28069390
45.

Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.

Remon J, Besse B.

Curr Opin Oncol. 2017 Mar;29(2):97-104. doi: 10.1097/CCO.0000000000000351. Review.

PMID:
28059852
46.

In-line monitoring of compaction properties on a rotary tablet press during tablet manufacturing of hot-melt extruded amorphous solid dispersions.

Grymonpré W, Verstraete G, Van Bockstal PJ, Van Renterghem J, Rombouts P, De Beer T, Remon JP, Vervaet C.

Int J Pharm. 2017 Jan 30;517(1-2):348-358. doi: 10.1016/j.ijpharm.2016.12.033. Epub 2016 Dec 14.

PMID:
27988376
47.

The use of partially hydrolysed polyvinyl alcohol for the production of high drug-loaded sustained release pellets via extrusion-spheronisation and coating: In vitro and in vivo evaluation.

Verstraete G, De Jaeghere W, Vercruysse J, Grymonpré W, Vanhoorne V, Stauffer F, De Beer T, Bezuijen A, Remon JP, Vervaet C.

Int J Pharm. 2017 Jan 30;517(1-2):88-95. doi: 10.1016/j.ijpharm.2016.11.067. Epub 2016 Dec 2.

PMID:
27919698
48.

Elucidation and visualization of solid-state transformation and mixing in a pharmaceutical mini hot melt extrusion process using in-line Raman spectroscopy.

Van Renterghem J, Kumar A, Vervaet C, Remon JP, Nopens I, Vander Heyden Y, De Beer T.

Int J Pharm. 2017 Jan 30;517(1-2):119-127. doi: 10.1016/j.ijpharm.2016.11.065. Epub 2016 Dec 1.

PMID:
27916700
49.

A consensus statement on the gender perspective in lung cancer.

Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J.

Clin Transl Oncol. 2017 May;19(5):527-535. doi: 10.1007/s12094-016-1578-x. Epub 2016 Nov 24. Review.

PMID:
27885542
50.

Supplemental Content

Support Center